X

Trial Profile

Phase 1/2 Study of Bosutinib in Patients With Amyotrophic Lateral Sclerosis (ALS)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 10 Mar 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bosutinib (Primary)
Indications Amyotrophic lateral sclerosis
Focus Adverse reactions
Acronyms iDReAM

Most Recent Events

27 Feb 2023 Phase changed from phase 1 to phase 1/2. Number of arms changed from 1 to 2. Experimental: Drug: Bosutinib (Phase 2 part) arm added to study protocol. Planned number of patients also increased. Primary and secondary outcome measures amended. Eligibility criteria amended to 20-75 years.
27 Feb 2023 Planned number of patients changed from 24 to 49.
27 Feb 2023 Planned End Date changed from 31 May 2021 to 31 Mar 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com